S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Closing prices for crude oil, gold and other commodities
The Senate passes a reauthorization of a key US surveillance program just after a midnight deadline
MarketBeat Week in Review – 4/15 - 4/19
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Closing prices for crude oil, gold and other commodities
The Senate passes a reauthorization of a key US surveillance program just after a midnight deadline
MarketBeat Week in Review – 4/15 - 4/19
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Closing prices for crude oil, gold and other commodities
The Senate passes a reauthorization of a key US surveillance program just after a midnight deadline
MarketBeat Week in Review – 4/15 - 4/19
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Closing prices for crude oil, gold and other commodities
The Senate passes a reauthorization of a key US surveillance program just after a midnight deadline
MarketBeat Week in Review – 4/15 - 4/19
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
OTCMKTS:IMMVF

Immunovia AB (publ) (IMMVF) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$0.15
$0.15
50-Day Range
N/A
52-Week Range
$0.84
$2.00
Volume
N/A
Average Volume
12,942 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
IMMVF stock logo

About Immunovia AB (publ) Stock (OTCMKTS:IMMVF)

Immunovia AB (publ), a diagnostic company, engages in developing and commercializing blood tests for the early detection of cancer and autoimmune diseases based on its proprietary test platform IMMray in Sweden and internationally. Its pipeline comprises early-phase research projects in collaboration with academic centers; and diagnostic tests in pancreatic cancer and rheumatoid arthritis diagnostics. Immunovia AB (publ) was founded in 2007 and is headquartered in Lund, Sweden.

IMMVF Stock News Headlines

Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
Immunovia Publishes Interim Report Jan-Sep 2022
Immunovia AB: Invitation to Immunovia's Q3 presentation
Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
Invitation to Immunovia's Q3 presentation
Attendo International publ AB (ATTE)
Immunovia publ AB (IMMNOV)
Immunovia Publishes Interim Report Jan-June 2022
Invitation to Immunovia's Q2 presentation
PanFAM-1 Results Partly Inconclusive
See More Headlines
Receive IMMVF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunovia AB (publ) and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/29/2013
Today
4/20/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
OTCMKTS:IMMVF
CIK
N/A
Fax
N/A
Employees
69
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Patrik Dahlen
    Chief Exec. Officer
  • Mr. Hans Liljenborg (Age 63)
    Chief Financial Officer
  • Ms. Lotta Blomgren (Age 61)
    Operations Director
  • Mr. Rolf Ehrnström (Age 68)
    Chief Scientific Officer
  • Ms. Laura Chirica (Age 53)
    Chief Commercial Officer
  • Mr. Henrik Winther (Age 55)
    Sr. VP of Bus. Devel.
  • Mr. Michael Pettigrew
    Sr. VP of Sales - North America
  • Ms. Linda Dexlin Mellby (Age 42)
    VP of R&D
  • Dr. Thomas C. King (Age 63)
    Medical Director

IMMVF Stock Analysis - Frequently Asked Questions

Are investors shorting Immunovia AB (publ)?

Immunovia AB (publ) saw a decrease in short interest during the month of March. As of March 15th, there was short interest totaling 14,800 shares, a decrease of 9.2% from the February 29th total of 16,300 shares. Based on an average trading volume of 0 shares, the days-to-cover ratio is presently ∞ days.
View Immunovia AB (publ)'s Short Interest
.

How were Immunovia AB (publ)'s earnings last quarter?

Immunovia AB (publ) (OTCMKTS:IMMVF) announced its quarterly earnings results on Friday, November, 29th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.01.

This page (OTCMKTS:IMMVF) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners